Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 5
Submit an article Journal homepage
339
Views
17
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Phase II study of first-line 131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic 18F-fluorodeoxyglucose positron emission tomography

Andrew D. McQuillanDepartment of Hematology, Fremantle Hospital, The University of Western Australia, Fremantle, Australia
,
William B. G. MacdonaldDepartment of Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Fremantle, Australia
&
J. Harvey TurnerDepartment of Nuclear Medicine, Fremantle Hospital, The University of Western Australia, Fremantle, AustraliaCorrespondence[email protected]
Pages 1271-1277 | Received 06 Jun 2014, Accepted 24 Jul 2014, Published online: 19 Aug 2014

Citations (17)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Stefano Luminari & Judith Trotman. (2015) Positron emission tomography–computed tomography in follicular lymphoma: “one fit for all”?. Leukemia & Lymphoma 56:5, pages 1191-1192.
Read now

Articles from other publishers (16)

Murali Kesavan & J. Harvey Turner. (2022) Myeloid Toxicity of Radionuclide Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals 37:3, pages 164-172.
Crossref
Maria Cristina Oliveira & João D. G. Correia. (2022) Clinical application of radioiodinated antibodies: where are we?. Clinical and Translational Imaging 10:2, pages 123-162.
Crossref
Francesco Cicone, Anna Sarnelli, Claretta Guidi, Maria Luisa Belli, Mahila Esmeralda Ferrari, Richard Wahl, Marta Cremonesi & Giovanni Paganelli. (2022) Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting. Seminars in Nuclear Medicine 52:2, pages 191-214.
Crossref
Murali Kesavan, Ghassan Zammar, James T. McQuillan, William B. G. Macdonald, J. Harvey Turner & Andrew D. McQuillan. (2021) Long‐term efficacy and safety of chemotherapy‐free first‐line iodine‐131‐rituximab radioimmunotherapy of follicular lymphoma. British Journal of Haematology 196:1, pages 237-241.
Crossref
Arif Sheikh, Shazia Fatima, Zain Khurshid & Zaheer Chiragh. 2022. Nuclear Medicine and Immunology. Nuclear Medicine and Immunology 359 432 .
Aurélie Rondon, Jacques Rouanet & Françoise Degoul. (2021) Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials. Cancers 13:21, pages 5570.
Crossref
Shozo Okamoto, Tohru Shiga & Nagara Tamaki. (2021) Clinical Perspectives of Theranostics. Molecules 26:8, pages 2232.
Crossref
Oke Gerke, Karen Ehlers, Edith Motschall, Poul Flemming Høilund-Carlsen & Werner Vach. (2019) PET/CT-Based Response Evaluation in Cancer—a Systematic Review of Design Issues. Molecular Imaging and Biology 22:1, pages 33-46.
Crossref
Kazuhiro Kitajima, Masaya Okada, Toru Kashiwagi, Kyoko Yoshihara, Tazuko Tokugawa, Akihiro Sawada, Satoshi Yoshihara, Yoshihiro Fujimori & Koichiro Yamakado. (2019) Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?. European Radiology 29:7, pages 3935-3944.
Crossref
J. Harvey Turner. (2019) Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More. Cancer Biotherapy and Radiopharmaceuticals 34:3, pages 135-140.
Crossref
J Harvey Turner. (2018) Recent advances in theranostics and challenges for the future. The British Journal of Radiology 91:1091, pages 20170893.
Crossref
Mayur S. Narkhede & Bruce D. Cheson. (2018) Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia 18:7, pages 447-451.
Crossref
Mahsa Eskian, MirHojjat Khorasanizadeh, Pier L Zinzani & Nima Rezaei. (2018) Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy 10:8, pages 699-711.
Crossref
Martin R Gill, Nadia Falzone, Yong Du & Katherine A Vallis. (2017) Targeted radionuclide therapy in combined-modality regimens. The Lancet Oncology 18:7, pages e414-e423.
Crossref
Murali Kesavan, Jan Boucek, William MacDonald, Andrew McQuillan & J. Turner. (2017) Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy. Diagnostics 7:2, pages 26.
Crossref
Mahsa Eskian, MirHojjat Khorasanizadeh, Francoise Kraeber-Bodere & Nima Rezaei. (2016) Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response. Critical Reviews in Oncology/Hematology 107, pages 182-189.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.